FTC Concerns Prompt Mylan to Give Up Two Generics for Meda

Mylan has agreed to shed two generics that treat muscle pain and epilepsy to allay FTC antitrust concerns, clearing the way for its $7.2 billion acquisition of Meda.

Under the FTC settlement, Mylan committed to selling off its generic version of felbamate tablets that treat epilepsy to Alvogen Pharma. The FTC noted that Mylan and Meda are two of the only three companies that produce 400 mg and 600 mg doses of the drug.

The agreement also requires Mylan to relinquish its U.S. marketing rights to Indicus Pharma for generics of carisoprodol, which treat muscle pain. Meda and Indicus are the only companies that currently produce the 250 mg dose of the drug.